Clinical Trial Update: Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intermittent moxifloxacin therapy to prevent acute exacerbations in chronic bronchitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis

Drugs mentioned

• Avelox (moxifloxacin)

Snippet

Sponsor: Bayer | Conditions: Lung Diseases, Bronchitis, Chronic | Phase 3 | Status: COMPLETED